At the news
? BEARISHIMPACT 6/10 PRESS-RELEASE filed May 15, 2026 at 16:05 ET
Outlook Therapeutics reported Q2 FY2026 results with GAAP net loss of $0.05/share (vs consensus $-0.12) and adjusted net loss of $0.16/share (vs consensus $-0.12). Revenue was $128K from initial LYTENAVA sales in Europe, but unit sales declined ~10% QoQ. The company completed a formal FDA dispute resolution meeting in April and expects a decision in May 2026, while cash stood at $7.7M (pre-April $4.2M offering).
- GAAP net loss per share: $(0.05) vs consensus $(0.12), beat on GAAP basis due to $9.3M in non-cash gains (warrant liability + promissory note fair value changes)
- Adjusted (non-GAAP) net loss per share: $(0.16) vs consensus $(0.12), miss of 33% on the Street metric
- Revenue: $128K from LYTENAVA European sales, down ~10% QoQ from Dec 2025 quarter
- Cash and equivalents: $7.7M as of March 31, 2026 (excluding $4.2M net from April 2026 registered direct offering)
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access